

10/522,303

=> file caplus
FILE 'CAPLUS' ENTERED AT 13:16:22 ON 13 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 May 2008 VOL 148 ISS 20
FILE LAST UPDATED: 12 May 2008 (20080512/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> d que

L1

STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

L3 18 SEA FILE=REGISTRY SSS FUL L1

L4 1 SEA FILE=CAPLUS L3

=> d l4 ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:120718 CAPLUS
DOCUMENT NUMBER: 140:164232
TITLE: Preparation of pyrrolidine derivatives as tryptase inhibitors
INVENTOR(S): Martin, Thomas; Ulrich, Wolf-Ruediger
PATENT ASSIGNEE(S): Altana Pharma AG, Germany
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004012731	A1	20040212	WO 2003-EP8127	20030724
W: AE, AL, AU, BA, BR, CA, CN, CO, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2492830	A1	20040212	CA 2003-2492830	20030724
AU 2003250162	A1	20040223	AU 2003-250162	20030724
EP 1534267	A1	20050601	EP 2003-766278	20030724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005535685	T	20051124	JP 2004-525300	20030724
US 20050256171	A1	20051117	US 2005-522303	20050125
PRIORITY APPLN. INFO.:			EP 2002-16683	A 20020726
			WO 2003-EP8127	W 20030724


OTHER SOURCE(S): MARPAT 140:164232

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB The title compds. I [X = -CH=C-, -CH=N-, S, or O; R1 = hydroxycarbonyl or alkoxy carbonyl; B1, B2 = O, NH, -O(CH₂)_mO-, -O(CH₂)_mNH-, where m = 1-4; K1 = -B3-Z1-B5-X1-; K2 = -B4-Z2-B6-X2-; B3, B4, B5, B6 = a bond or C1-C2 alkylene; X1, X2 = amino, aminocarbonyl, amidino, or guanidino; Z1, Z2 = 2,5-pyridinylene, 3,6-pyridinylene, 2,4-pyridinylene, 1,3-phenylene, 1,4-phenylene, 1,3-cyclohexylene, or 1,4-cyclohexylene; R2 = C(O)OR₃ or C(O)N(R₄)R₅, where R₃ = H, alkyl, cycloalkyl, cycloalkylmethyl, or benzyl, R₄, R₅ = H, alkyl, cycloalkyl, cycloalkylmethyl or N(R₄)R₅ = 1-pyrrolidinyl, 1-piperidinyl, 1-hexahydroazepinyl, 1-piperazinyl, or 4-morpholinyl; Y = -OCH₂-, -CH₂O- or absent] were prepared as tryptase inhibitors. Thus, reaction of Me [3-{3-[3-(tert-butoxycarbonylaminomethyl)benzylaminocarbonyloxy]prop-1-ynyl}-5-(3-hydroxyprop-1-ynyl)phenyl]acetate (preparation given) with N,N-carbonyldiimidazole and Me 4-amino-1-{3-[3-(tert-butoxycarbonylaminomethyl)phenyl]propanoyl}pyrrolidine-2-carboxylate (preparation given) followed by acid hydrolysis gave compound II. The latter inhibited human tryptase with pK_{app} = 8.62.
- IT 654676-96-7P 654677-02-8P 654677-08-4P
 654677-15-3P 654677-23-3P 654677-29-9P
 654677-35-7P 654677-43-7P 654677-48-2P
 654677-54-0P 654677-61-9P 654677-65-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrrolidine derivs. as tryptase inhibitors)
- RN 654676-96-7 CAPLUS
- CN L-Proline, 4-[[[3-[3-[3-[[[3-(aminomethyl)phenyl]methyl]amino]carbonyl]oxy]-1-propynyl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propynyl]oxyl]carbonyl]amino]-1-[3-[3-(aminomethyl)phenyl]-1-oxopropyl]-, methyl ester, dihydrochloride, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl




RN 654677-02-8 CAPLUS

CN L-Proline, 4-[[[[[3-[3-[3-[[[[[3-(aminomethyl)phenyl]methyl]amino]carbonyl]oxy]-1-propynyl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propynyl]oxy]carbonyl]amino]-1-[3-[4-(aminomethyl)phenyl]-1-oxopropyl]-, methyl ester, dihydrochloride, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl




RN 654677-08-4 CAPLUS


CN L-Proline, 1-[3-[3-(aminomethyl)phenyl]-1-oxopropyl]-4-[[[[[3-[3-[3-[[(6-
amino-3-pyridinyl)methyl]amino]carbonyl]oxy]-1-propynyl]-5-(2-methoxy-2-
oxoethyl)phenyl]-2-propynyl]oxy]carbonyl]amino]-, methyl ester,
dihydrochloride, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

●₂ HCl

PAGE 1-B




RN 654677-15-3 CAPLUS

CN L-Proline, 1-[3-[4-(aminomethyl)phenyl]-1-oxopropyl]-4-[[[[[3-[3-[3-[[(6-
amino-3-pyridinyl)methyl]amino]carbonyl]oxy]-1-propynyl]-5-(2-methoxy-2-
oxoethyl)phenyl]-2-propynyl]oxy]carbonyl]amino]-, methyl ester,
dihydrochloride, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



●2 HCl


PAGE 1-B




RN 654677-23-3 CAPLUS

CN L-Proline, 1-[3-[4-(aminomethyl)phenyl]-1-oxopropyl]-4-[[[[[3-[3-[3-[[[(2-
amino-4-pyridinyl)methyl]amino]carbonyl]oxy]-1-propynyl]-5-(2-methoxy-2-
oxoethyl)phenyl]-2-propynyl]oxy]carbonyl]amino]-, methyl ester,
dihydrochloride, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl




RN 654677-29-9 CAPLUS

CN L-Proline, 1-[3-[3-(aminomethyl)phenyl]-1-oxopropyl]-4-[[[3-[3-[3-[(2-amino-4-pyridinyl)methyl]amino]carbonyloxy]-1-propynyl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propynyl]oxy]carbonylamino]-, methyl ester, dihydrochloride, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● 2 HCl

PAGE 1-B





RN 654677-35-7 CAPLUS

CN L-Proline, 4-[[[[[3-[3-[3-[[[[3-(aminomethyl)phenyl]methyl]amino]carbonyl]oxy]-1-propyn-1-yl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-1-[3-(aminomethyl)phenyl]-1-oxopropyl-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 654677-43-7 CAPLUS

CN L-Proline, 4-[[[3-[3-[3-[[[[3-(aminomethyl)phenyl]methyl]amino]carbonyl]oxy]-1-propyn-1-yl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-1-[3-[4-(aminomethyl)phenyl]-1-oxopropyl]-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 654677-48-2 CAPLUS


CN L-Proline, 1-[3-[3-(aminomethyl)phenyl]-1-oxopropyl]-4-[[[3-[3-[3-[[[(6-amino-3-pyridinyl)methyl]amino]carbonyl]oxy]-1-propyn-1-yl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 654677-54-0 CAPLUS

CN L-Proline, 1-[3-[4-(aminomethyl)phenyl]-1-oxopropyl]-4-[[[[[3-[3-[3-[[(6-
amino-3-pyridinyl)methyl]amino]carbonyl]oxy]-1-propyn-1-yl]-5-(2-methoxy-2-
oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-, methyl ester, (4S)-
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 654677-61-9 CAPLUS

CN L-Proline, 1-[3-[4-(aminomethyl)phenyl]-1-oxopropyl]-4-[[[[3-[3-[3-[[(2-amino-4-pyridinyl)methyl]amino]carbonyl]oxy]-1-propyn-1-yl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-, methyl ester, (4S)-(CA INDEX NAME)

Absolute stereochemistry.




RN 654677-65-3 CAPLUS


CN L-Proline, 1-[3-[3-(aminomethyl)phenyl]-1-oxopropyl]-4-[[[[3-[3-[3-[[(2-amino-4-pyridinyl)methyl]amino]carbonyl]oxy]-1-propyn-1-yl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-, methyl ester, (4S)-(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 654677-69-7P 654677-73-3P 654677-80-2P
654677-83-5P 654677-89-1P 654677-96-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolidine derivs. as tryptase inhibitors)

RN 654677-69-7 CAPLUS


CN L-Proline, 4-[[[[[3-[3-[[[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methylyl]phenyl]methyl]amino]carbonyloxy]-1-propyn-1-yl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-1-[3-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-oxopropyl]-, methyl ester,
(4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




— OMe




RN 654677-73-3 CAPLUS

CN L-Proline, 4-[[[[3-[3-[3-[[[[3-[[(1,1-dimethylethoxy)carbonyl]amino]methylyl]phenyl]methyl]amino]carbonyloxy]-1-propyn-1-yl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-1-[3-[4-[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-oxopropyl-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.





— OMe



RN 654677-80-2 CAPLUS
 CN L-Proline, 1-[3-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-oxopropyl]-4-[[[3-[3-[3-[[[[6-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-pyridinyl]methyl]amino]carbonyl]oxy]-1-propyn-1-yl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-, methyl ester, (4S)-
 (CA INDEX NAME)

Absolute stereochemistry.







RN 654677-83-5 CAPLUS

CN L-Proline, 1-[3-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-oxopropyl]-4-[[[3-[3-[3-[[[[6-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-pyridinyl]methyl]amino]carbonyl]oxy]-1-propyn-1-yl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-, methyl ester, (4S)-
(CA INDEX NAME)


Absolute stereochemistry.






RN 654677-89-1 CAPLUS
 CN L-Proline, 1-[3-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-oxopropyl]-4-[[[3-[3-[3-[[[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]amino]carbonyl]oxy]-1-propyn-1-yl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-, methyl ester, (4S)-(CA INDEX NAME)


Absolute stereochemistry.






RN 654677-96-0 CAPLUS
 CN L-Proline, 1-[3-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1-oxopropyl]-4-[[[3-[3-[3-[[[[2-[(1,1-dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]amino]carbonyl]oxy]-1-propyn-1-yl]-5-(2-methoxy-2-oxoethyl)phenyl]-2-propyn-1-yl]oxy]carbonyl]amino]-, methyl ester, (4S)-(CA INDEX NAME)

Absolute stereochemistry.





=>